Corrigendum to "Cholesterol-Lowering Probiotics as Potential Biotherapeutics for Metabolic Diseases"
J Diabetes Res
.
2022 Apr 1:2022:3952529.
doi: 10.1155/2022/3952529.
eCollection 2022.
Authors
Manoj Kumar
1
,
Ravinder Nagpal
2
,
Rajesh Kumar
1
,
R Hemalatha
1
,
Vinod Verma
3
,
Ashok Kumar
4
,
Chaitali Chakraborty
5
,
Birbal Singh
6
,
Francesco Marotta
7
,
Shalini Jain
8
,
Hariom Yadav
8
Affiliations
1
Department of Microbiology & Immunology, National Institute of Nutrition, Hyderabad, India.
2
Department of Biotechnology, JMIT Institute of Technology, Radaur, Haryana, India.
3
Research and Development Unit, National Heart Centre, Singapore.
4
Department of Zoology, M.L.K. Post-Graduate College, Balrampur, India.
5
Department of Biotechnology, ITS Paramedical College, Ghaziabad, India.
6
Indian Veterinary Research Institute, Regional Station, Palampur, India.
7
Hepato-Gastroenterology Unit, S. Giuseppe Hospital, Vittore, Milano, Italy.
8
National Institute of Diabetes and Digestive and Kidney Diseases, NIH, MD, USA.
PMID:
35399706
PMCID:
PMC8993570
DOI:
10.1155/2022/3952529
Abstract
[This corrects the article DOI: 10.1155/2012/902917.].
Copyright © 2022 Manoj Kumar et al.
Publication types
Published Erratum